You are viewing archived content
Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.
Figure PPP-1. Indexed trends in EU retail prices for major drug types, adjusting for inflation, 2003–08
Notes:
1. The trends represent the available information on national street-level prices for each drug in the EU Member States and Norway, weighted by country population sizes to form an overall EU trend. Prices have been adjusted for national inflation rates (base year 2003) and all series indexed to a base of 100 in 2003.
2. Countries missing drug price information for two or more consecutive years are not included in the trend calculations: the trend for LSD is based on twelve countries (74 % of the EU population 15-64), heroin brown on eight countries (39 % of the EU population 15-64), amphetamine on thirteen countries (74 % of the EU population 15-64), cocaine on fifteen countries (71 % of the EU population 15-64), ecstasy on fourteen countries (75 % of the EU population 15-64), herbal cannabis on fifteen countries (70 % of the EU population 15-64), and cannabis resin on fifteen countries (78 % of the EU population 15-64).
3. Additionally, where 2008 data are missing (seventeen cases) 2007 prices are used; for missing 2003 data (forty-seven cases) 2004 prices are used; data missing for other years (twenty-five cases) have been interpolated from adjacent years.
Sources:
Price data: Reitox national focal points
(see the help page for information about formats etc.)